FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE "ROSSIJSKIJ NAUCHNYJ TSENTR RADIOLOGII I KHIRURGICHESKIKH TEKHNOLOGIJ IMENI AKADEMIKA A.M. GRANOVA" MINISTERSTVA ZDRAVOOKHRANENIYA ROSSIJSKOJ FEDERA
发明人:
Pavlovskij Aleksandr Vasilevich (RU),Павловский Александр Васильевич (RU),Moiseenko Vladislav Evgenevich (RU),Моисеенко Владислав Евгеньевич (RU),Popov Sergej Aleksandrovich (RU),Попов Сергей Александ
申请号：
RU2019124140
公开号：
RU0002706341C1
申请日:
2019.07.24
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, and aims at treating inoperable pancreatic head adenocarcinoma (AP). An intra-arterial infusion introduction is 50 mg/m2 Oxaliplatin for 20 minutes through a catheter inserted into a gastroduodenal artery. Then bolus is added with suspension 50 mg/m2 Abraxane in at least 5 ml of Lipiodol. Catheter is then reinserted into the celiac and intra-arterially infusion 1,000 mg/m2 Gemcitabin for one hour. After the chemotherapy is completed, sessions of conformal radiation therapy are performed by multifractionation daily with fractions of 2 Gy 2 times a day at intervals of at least 6 hours between them to a total physical focal dose of 50 Gy, which is equivalent to 60 Gy of normal fractionation. That is followed by systematic chemotherapy by oral administration of Capecitabin daily at 2,500 mg/m2 per day in 2 divided doses in the morning and in the evening for no more than 14 days. Not earlier than 2 weeks later, chemoinfusion with Oxaliplatin and chemoembolization with Abraxane in Lipiodol are repeatedly repeated in the same regimens with subsequent infusion of Gemcitabin into the celiac and oral administration of Capecitabin for no more than 14 days not more than once a month for not more than 4 months or until occurrence of adverse events II-III degree, or progression of tumor process according to RECIST criteria.EFFECT: use of the invention provides achieving a positive therapeutic effect with a satisfactory state of patients, allowing to continue such treatment more than once.1 cl, 1 exИзобретение относится к области медицины, а именно к онкологии, и предназначено для лечения неоперабельной аденокарциномы головки поджелудочной железы (АПЖ). Осуществляют внутриартериальное инфузионное введение 50 мг/м2 оксалиплатина в течение 20 минут через катетер, установленный в гастродуоденальную артерию. Затем болюсно вводят суспензию 50 мг/м2 абраксана не более чем в 5 мл липиодола. После этого катетер п
